NKP-1339, a first-in-class anticancer drug showing mild side effects and activity in patients suffering from advanced refractory cancer

Detalles Bibliográficos
Autores principales: Trondl, Robert, Heffeter, Petra, Jakupec, Michael A, Berger, Walter, Keppler, Bernhard K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Meeting Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3506350/
http://dx.doi.org/10.1186/2050-6511-13-S1-A82
_version_ 1782250896120348672
author Trondl, Robert
Heffeter, Petra
Jakupec, Michael A
Berger, Walter
Keppler, Bernhard K
author_facet Trondl, Robert
Heffeter, Petra
Jakupec, Michael A
Berger, Walter
Keppler, Bernhard K
author_sort Trondl, Robert
collection PubMed
description
format Online
Article
Text
id pubmed-3506350
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35063502012-11-29 NKP-1339, a first-in-class anticancer drug showing mild side effects and activity in patients suffering from advanced refractory cancer Trondl, Robert Heffeter, Petra Jakupec, Michael A Berger, Walter Keppler, Bernhard K BMC Pharmacol Toxicol Meeting Abstract BioMed Central 2012-09-17 /pmc/articles/PMC3506350/ http://dx.doi.org/10.1186/2050-6511-13-S1-A82 Text en Copyright ©2012 Trondl et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Meeting Abstract
Trondl, Robert
Heffeter, Petra
Jakupec, Michael A
Berger, Walter
Keppler, Bernhard K
NKP-1339, a first-in-class anticancer drug showing mild side effects and activity in patients suffering from advanced refractory cancer
title NKP-1339, a first-in-class anticancer drug showing mild side effects and activity in patients suffering from advanced refractory cancer
title_full NKP-1339, a first-in-class anticancer drug showing mild side effects and activity in patients suffering from advanced refractory cancer
title_fullStr NKP-1339, a first-in-class anticancer drug showing mild side effects and activity in patients suffering from advanced refractory cancer
title_full_unstemmed NKP-1339, a first-in-class anticancer drug showing mild side effects and activity in patients suffering from advanced refractory cancer
title_short NKP-1339, a first-in-class anticancer drug showing mild side effects and activity in patients suffering from advanced refractory cancer
title_sort nkp-1339, a first-in-class anticancer drug showing mild side effects and activity in patients suffering from advanced refractory cancer
topic Meeting Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3506350/
http://dx.doi.org/10.1186/2050-6511-13-S1-A82
work_keys_str_mv AT trondlrobert nkp1339afirstinclassanticancerdrugshowingmildsideeffectsandactivityinpatientssufferingfromadvancedrefractorycancer
AT heffeterpetra nkp1339afirstinclassanticancerdrugshowingmildsideeffectsandactivityinpatientssufferingfromadvancedrefractorycancer
AT jakupecmichaela nkp1339afirstinclassanticancerdrugshowingmildsideeffectsandactivityinpatientssufferingfromadvancedrefractorycancer
AT bergerwalter nkp1339afirstinclassanticancerdrugshowingmildsideeffectsandactivityinpatientssufferingfromadvancedrefractorycancer
AT kepplerbernhardk nkp1339afirstinclassanticancerdrugshowingmildsideeffectsandactivityinpatientssufferingfromadvancedrefractorycancer

Ejemplares similares